Ascentage Pharma Sets AGM to Approve 2025 Accounts, Board Mandates and Share Issue Authority

Ascentage Pharma Group International ( (HK:6855) ) has issued an update.

Ascentage Pharma Group International has called its annual general meeting for May 20, 2026, in Suzhou, China, where shareholders will vote on key corporate matters, including adoption of the 2025 audited financial statements and reports. The meeting will also consider the re-election of three non-executive and independent non-executive directors, authorization for the board to set director pay, re-appointment of Ernst & Young as auditor, and the grant of a general mandate allowing the board to issue up to 20% of the company’s share capital, potentially enhancing financial flexibility and future fundraising options.

These agenda items, standard for a listed biopharmaceutical issuer, underline continuity in the company’s governance, with existing directors and auditors slated to remain in place. The proposed share issuance mandate, subject to shareholder approval, would give the board additional capital markets tools to support strategic initiatives, while still being bounded by Hong Kong listing rules and shareholder oversight.

The most recent analyst rating on (HK:6855) stock is a Buy with a HK$93.00 price target. To see the full list of analyst forecasts on Ascentage Pharma Group International stock, see the HK:6855 Stock Forecast page.

More about Ascentage Pharma Group International

Ascentage Pharma Group International is a Cayman Islands–incorporated biopharmaceutical company listed in Hong Kong, focusing on the research and development of innovative therapies. The company operates in China with activities centered in locations such as Suzhou Industrial Park, positioning itself within the broader life sciences and healthcare sector.

Average Trading Volume: 2,195,586

Technical Sentiment Signal: Hold

Current Market Cap: HK$17.33B

For an in-depth examination of 6855 stock, go to TipRanks’ Overview page.